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Background: Tobacco smoking is one of the main risk factors for oral, pharyngeal and oesophageal cancers
in developed countries. Information on the role of the tar yield of cigarettes in upper digestive tract carcino-
genesis is sparse and needs to be updated because the tar yield of cigarettes has steadily decreased over the last
few decades.
Patients and methods: We analysed two case–control studies, from Italy and Switzerland, conducted
between 1992 and 1999, involving 749 cases of oral and pharyngeal cancer and 1770 controls, and 395 cases
of squamous-cell oesophageal carcinoma and 1066 matched controls. Odds ratios (ORs) were estimated by
unconditional multiple logistic regression models, including terms for age, sex, study centre, education and
alcohol consumption.
Results: Based on the brand of cigarettes smoked for the longest time, the multivariate ORs for current
smokers compared with never smokers were 6.1 for <20 mg and 9.8 for ≥20 mg tar for oral and pharyngeal
neoplasms, and 4.8 and 5.4 for oesophageal cancer, respectively. For the cigarette brand smoked in the previ-
ous six months, the ORs for ≥10 mg compared with <10 mg were 1.9 for cancer of the oral cavity and pharynx
and 1.8 for oesophageal cancer, after allowance for number of cigarettes and duration of smoking.
Conclusions: The present study confirms the direct relationship between the tar yield of cigarettes and upper
digestive tract neoplasms, and provides innovative information on lower tar cigarettes, which imply reduced
risks compared with higher tar ones. However, significant excess risks were observed even in the lower tar
category, thus giving unequivocal indications for stopping smoking as a priority for prevention of upper
digestive tract neoplasms.
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Introduction
Tobacco smoking is, together with drinking alcohol, the
major risk factor for oral, pharyngeal and oesophageal cancer in
developed countries [1–9]. Different types of tobacco products
(cigarettes, cigars, pipes, betel chewing and snuff) increase the
risk of upper digestive tract neoplasms [5, 10–15], although pre-
cise quantification of their risk is still open to discussion.
With reference to the role of type or tar yield of cigarettes,
a case–control study conducted in Northern Italy, based on
291 males with cancer of the oral cavity and pharynx and 288
with cancer of the oesophagus, reported odds ratios (ORs) of 2.3
for oral and pharyngeal cancer in high-tar cigarette smokers com-
pared with low-tar ones, and 2.8 for oesophageal cancer [3, 4]. A
case–control study from the USA, based on 1009 oral cavity and
pharyngeal cancer cases, found ORs of 2.1 for men and 4.6 for
women for the highest category of cumulative lifetime exposure
to cigarette tar compared with never smokers [16]. A multicentre
case–control study on cancers of the hypopharynx and larynx,
from France, Switzerland, Italy and Spain, found a relative risk for
hypopharyngeal cancer of 2.2 among smokers of black tobacco
(which tends to have higher tar yield) compared with blond [17].
A case–control study from France found that black/dark tobacco
and non filter-tipped cigarettes were associated with an increased
risk of oesophageal cancer compared with light filter-tipped
cigarettes and mild tobacco [12]. Furthermore, an investigation
based on 830 subjects with oesophageal cancer, from five hospital-
based case–control studies conducted in South America, found
an increased risk in black tobacco-type cigarette smokers com-
pared to smokers of the blond type, with ORs of 2.0 for men and
3.4 for women [7]. As yet no information is available on the risks
associated with newer very low tar yield cigarettes.
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The tar yield of cigarettes has steadily decreased over the last
few decades [18], and this may have influenced recent favourable
trends in mortality from upper digestive tract neoplasms in males
from several western European countries, following earlier rises
[19–22]. The average tar yield of Italian cigarettes was ∼25 mg in
the 1960s, ∼17 mg in 1983–1984 [23] and declined to ∼12 mg in
the late 1990s. To provide further information on the role of the
most recent cigarettes in relation to the risk of upper digestive
tract cancers, we analysed data from two multicentre case–
control studies conducted in Northern Italy and Switzerland.
Patients and methods
This analysis is based on data from two case–control studies on the upper
digestive tract cancer. The first one, on cancer of the oral cavity and pharynx,
was conducted between 1992 and 1997 in two Italian areas (the province of
Pordenone, Northern Italy, and those of Rome and Latina, Central Italy) and
in the Swiss Canton of Vaud [24, 25]. The second one, on squamous-cell
oesophageal cancer, was conducted between 1992 and 1999 in the provinces
of Pordenone, Padua and Milan, Northern Italy [26], and in the Swiss Canton
of Vaud [25, 27].
The first study included 749 cases (634 men, 115 women) aged <77 years
(median 58 years) with incident, histologically confirmed cancers of the
oral cavity and pharynx, and 1770 hospital controls (1252 men, 518 women)
<78 years of age (median 58 years). Twenty-eight percent of controls were
admitted to hospital for traumas, 25% for non-traumatic orthopaedic
conditions, 24% for acute surgical disorders and 23% for miscellaneous other
illnesses (including skin, eye or ear disorders).
The second study included 395 cases (351 men, 44 women) <77 years of
age (median 60 years) with incident, histologically confirmed squamous-cell
oesophageal cancer, and 1066 hospital controls (875 men, 191 women) aged
<75 years (median 60 years). Controls were matched with cases by age
(within 5 year intervals), sex and study centre, with a control:case ratio of ∼5
for women and ∼2 for men. Twenty-nine percent of controls were admitted
for traumas, 36% for non-traumatic orthopaedic conditions, 12% for acute
surgical disorders and 23% for miscellaneous other illnesses. In both studies,
the response rate was >95% for cases and controls.
Trained interviewers collected data using structured questionnaires,
including information on sociodemographic characteristics, anthropometric
measures and lifestyle habits, such as smoking and alcohol consumption. The
questions on tobacco smoking included smoking status (never, ex, current
smoker), number of cigarettes or cigars and grams of tobacco for pipe smoked
per day, the age at starting and (for ex-smokers) the time since stopping
smoking, and brands of cigarette smoked. Each subject could indicate the
brands smoked for up to three periods of their life and, for current smokers,
the brand smoked during the previous 6 months. Reproducibility of the
information on tobacco smoking was satisfactory [28]. Tar yields of more
than 100 kinds of cigarette, i.e. the most common Italian and international
brands, were determined by the Laboratory of the British Government
Chemist for cigarettes smoked before 1983 [29], and obtained from published
sources by the Italian Government for dates thereafter [30]. Tar yield of Swiss
cigarettes was obtained from cigarette packets.
The cigarette brands were classified into three categories according to their
tar yield: high tar (≥20 mg), including older, mostly unfiltered cigarettes;
intermediate tar (10–19 mg); and low tar (<10 mg), including vented filter
cigarettes.
Odds ratios and corresponding 95% confidence intervals (CI) were esti-
mated by unconditional multiple logistic regression models [31], including
terms for age, sex, study centre, years of education and alcohol consumption.
For the comparison of high versus low tar yield categories the analyses were
restricted to ever and current smokers, and further terms for smoking status
(when required), the number of cigarettes smoked and the duration of the
habit were included in the models.
Results
Table 1 shows the multivariate ORs for cancers of the oral cavity
and pharynx and oesophagus according to selected measures of
tobacco smoking. Cigarette smoking was strongly associated to
the risk for both cancer sites; comparing current to never smokers,
the ORs were 6.8 for oral and pharyngeal cancer, and 5.1 for
oesophageal cancer (the ORs for ex-smokers were ∼2 for both
these cancers). The ORs increased with the number of cigarettes
smoked to 12.3 for oral and pharyngeal cancer, and 7.9 for oeso-
phageal cancer, for current smokers of ≥25 cigarettes per day. For
pipe and cigar smoking, the ORs were 6.6 for oral and pharyngeal
cancer, and 12.6 for oesophageal cancer. Increasing risks were
observed in relation to duration of smoking, with ORs of 7.7 for
oral and pharyngeal cancer, and of 5.5 for oesophageal cancer,
for current smokers for ≥30 years. Consistent patterns of risk with
dose and duration were also observed for ex-smokers.
The effect of tar yield among ever and current smokers is
presented in Table 2. When compared with never smokers, the
multivariate ORs for oral and pharyngeal cancer for ever smokers
were 4.2 for low/medium tar yield (<20 mg) and 5.9 for high tar
(≥20 mg). For oesophageal cancer, the OR was 3.5 in both strata.
A similar effect of tar yield was observed when considering
current smokers only: compared with never smokers, the multi-
variate ORs of oral and pharyngeal cancer were 6.1 for low/inter-
mediate tar yield and 9.8 for high tar, and those for oesophageal
cancer were 4.8 and 5.4, respectively. When considering the
cigarettes smoked in the last 6 months, the ORs for oral and
pharyngeal cancer were 3.8 for low (<10 mg) and 7.1 for inter-
mediate/high tar yield (≥10 mg). A similar pattern of risk was
found for oesophageal cancer, the ORs being 2.4 and 5.4 for low
and intermediate/high tar, respectively.
In Table 3, lower and higher tar yield cigarettes were compared
among ever and current smokers, after further allowance for
smoking status (when considering ever smokers), number of
cigarettes smoked and duration of habit. In ever smokers, the
ORs for ≥20 mg compared to <20 mg tar yield were 1.6 for cancer
of the oral cavity and pharynx, and 1.1 for cancer of the oeso-
phagus. Corresponding values in current smokers were 1.6 for
oral and pharyngeal cancer, and 1.3 for oesophageal cancer.
When considering the cigarette brand smoked in the previous
6 months, the ORs for ≥10 mg compared with <10 mg were 1.9
(95% CI 1.1–3.3) for cancer of the oral cavity and pharynx, and
1.8 (95% CI 0.8–4.1) for oesophageal cancer.
Discussion
The present study confirms and extends previous findings of
a relationship between the tar yield of cigarettes and upper
digestive tract neoplasms [3, 4, 7, 12, 16, 17].
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The most innovative findings of our investigation concern very
low tar (<10 mg) cigarettes. The large number of current smokers
allowed us to compare recent smokers of cigarettes with <10 mg
tar yield to higher tar ones. The ORs for current smokers of ≥10 mg
tar cigarettes compared with <10 mg were almost 2-fold for oral
and oesophageal cancers. These results are of particular relevance
because they were obtained after allowance for duration and
number of cigarettes. It is possible that low-tar smokers tend to
compensate in terms of number of cigarettes smoked. In fact, in
our data, current smokers of low yield cigarettes had an average
consumption of about one cigarette per day more than high tar
ones. Furthermore, smokers who switch from higher tar yield
cigarettes to lower ones tend to compensate for reduced tar yields
by taking larger puffs, puffing more frequently, and leaving a
shorter butt [19, 32].
The choice of considering the cigarette brand smoked for the
longest time could introduce some bias, since information on the
distant past is often imprecise and influenced by current or more
recent habits [3]. To avoid these possible misclassifications or
bias, we considered cases and controls who had smoked only one
cigarette brand lifelong (or brands of the same category of tar
yield) and found similar risks. The OR for oral and pharyngeal
cancers among current smokers with continual tar yield ≥20 mg
compared with never smokers was 10.6 (95% CI 6.1–18.4), and
that for oesophageal cancer was 9.6 (95% CI 4.6–20.1). How-
ever, current smokers who had smoked only high tar yield
cigarettes had a longer duration of the habit than those smoking
only low tar ones, since intermediate and low tar cigarettes have
become widespread in Southern Europe just over the last two to
three decades [29, 30].
To avoid possible sources of bias, cases and controls were
drawn from comparable catchment areas and participation was
almost complete. The results were not substantially modified by
allowance for potential major confounding factors, including
socioeconomic characteristics, alcohol consumption, duration
and amount of smoking. Information on cigarette smoking was
satisfactorily reproducible [28], and there is no reason to suppose
differential recall of brand type in cases and controls.
These results have important public health implications [33],
together with the evidence of lower excess risk for low tar
Table 1. Distribution of 749 cases of cancers of the oral cavity and pharynx and 1770 controls, and 395 cases of squamous-cell oesophageal 
cancer and 1066 controls according to selected tobacco variables, with corresponding odds ratios (OR) and 95% confidence intervals (CI). 
Northern Italy and Switzerland, 1992–1999.
aIn some strata the sum does not add up to the total due to some missing values.
bEstimates from unconditional multiple logistic regression models, including terms for age, sex, study centre, education and alcohol 
consumption.
cReference category.
Smoking habita Oral cavity and pharynx Oesophagus
Cases Controls ORb (95% CI) Cases Controls ORb (95% CI)
Never smokers 60 692 1c 37 376 1c
Current smokers 517 521 6.8 (4.9–9.4) 234 318 5.1 (3.3–7.7)
Cigarettes per day
<15 108 205 4.6 (3.1–6.7) 40 109 2.7 (1.6–4.7)
15–24 244 225 7.7 (5.3–11.0) 110 135 5.7 (3.5–9.1)
≥25 157 82 12.3 (7.9–19.0) 77 63 7.9 (4.5–13.8)
Pipe/cigar only 8 9 6.6 (2.0–21.3) 6 11 12.6 (3.6–43.6)
Total duration of smoking (years)
<30 126 214 5.1 (3.4–7.8) 32 83 3.3 (1.7–6.4)
≥30 391 307 7.7 (5.5–10.9) 202 234 5.5 (3.6–8.5)
Ex-smokers 172 557 2.1 (1.5–3.1) 124 372 2.2 (1.4–3.4)
Cigarettes per day
<15 41 200 1.7 (1.0–2.7) 31 132 1.7 (1.0–3.0)
≥15 125 347 2.3 (1.6–3.4) 90 230 2.5 (1.5–4.0)
Pipe/cigar only 4 6 4.4 (1.0–18.9) 2 7 1.9 (0.3–13.2)
Total duration of smoking (years)
<30 67 344 1.5 (1.0–2.3) 39 216 1.4 (0.8–2.4)
≥30 105 213 3.1 (2.1–4.6) 85 156 3.3 (2.0–5.3)
Time since smoking cessation (years)
<10 101 202 3.6 (2.4–5.4) 64 107 4.1 (2.5–7.0)
≥10 71 355 1.3 (0.9–2.0) 60 265 1.4 (0.9–2.3)
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cigarettes compared to high tar ones on lung [19, 32, 34] and
laryngeal cancers [3], and coronary heart diseases [19, 35].
Nevertheless, significant and substantial excess risks for the oral
cavity and pharynx and oesophagus were observed even in the
lower tar category, providing unequivocal indications for stop-
ping smoking as a priority for prevention of upper digestive tract
neoplasms.
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